BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//The European School of Multimodality Imaging & Therapy (ESMIT) - ECPv6.15.11//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:The European School of Multimodality Imaging & Therapy (ESMIT)
X-ORIGINAL-URL:https://esmit.eanm.org
X-WR-CALDESC:Events for The European School of Multimodality Imaging & Therapy (ESMIT)
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Europe/Vienna
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20240331T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20241027T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20250330T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20251026T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20260329T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20261025T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20270328T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20271031T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20280326T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20281029T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=Europe/Vienna:20251212T133000
DTEND;TZID=Europe/Vienna:20251212T143000
DTSTAMP:20260525T223814
CREATED:20241017T081824Z
LAST-MODIFIED:20251204T110136Z
UID:1944-1765546200-1765549800@esmit.eanm.org
SUMMARY:To AI or not to AI in Neurology: That is the Question
DESCRIPTION:This webinar will explore state-of-the-art AI approaches for advancing neuroimaging\, with a particular focus on quantitative PET. It will cover the entire imaging pipeline\, from preprocessing\, acquisition\, and tomographic reconstruction to quantification\, segmentation\, denoising\, and resolution enhancement\, demonstrating how modern AI can enable more reproducible and robust brain PET biomarkers. Through two expert presentations and practical case examples\, the webinar will showcase how AI-driven methodologies are reshaping neuroimaging research and supporting more accurate diagnosis and disease monitoring. \n\n\n\n \n\n\n\n \n\n\n\n\n\n\n\nRegister nowEnrol in the live webinar now for free! Register now\n\n\n\n\n\n\n\n \n\n\n\n \n\n\n\nLearning Objectives\n\n\n\n \n\n\n\n\nLearn the principles behind AI-based quantitative PET methods\n\n\n\nUnderstand how AI can enhance each stage of the neuroimaging pipeline\, from preprocessing and reconstruction to segmentation\, denoising\, and resolution recovery.\n\n\n\nCritically assess when AI meaningfully improves neuroimaging workflows\n\n\n\nRecognize emerging opportunities and challenges in integrating AI tools into brain PET\n\n\n\n\n \n\n\n\n \n\n\n\nTarget Audience\n\n\n\n \n\n\n\nNuclear physicians\, medical physicists\, imaging scientists and radiologists working in PET neuroimaging \n\n\n\n \n\n\n\nFaculty\n\n\n\n \n\n\n\n\n\nPablo Aguilar FernándezModerator \n\n\n\n\n\nDimitris VisvikisSpeaker \n\n\n\n\n\nCharalampos TsoumpasSpeaker \n\n\n\n\n\n\n\n\n\nEvent Overview
URL:https://esmit.eanm.org/event/to-ai-or-not-to-ai-in-neurology-that-is-the-question/
CATEGORIES:AI & Quantification,Live Webinars
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Vienna:20260227T000000
DTEND;TZID=Europe/Vienna:20270227T235959
DTSTAMP:20260525T223814
CREATED:20260512T122929Z
LAST-MODIFIED:20260512T123532Z
UID:3661-1772150400-1803772799@esmit.eanm.org
SUMMARY:EANM Focus Meeting 7: Molecular Imaging for a Personalised Treatment in Alzheimer's Disease
DESCRIPTION:Alzheimer’s disease is a growing global health concern\, now facing a pivotal moment with the approval of disease-specific treatments. \n\n\n\nThis Focus Meeting brought together international experts under the theme ‘An accurate diagnosis for an effective treatment with Molecular Imaging’ to explore the crucial role of imaging and biomarkers in improving diagnosis\, treatment selection\, and monitoring. \n\n\n\nThe goal was to reach a multidisciplinary consensus on the current state of the art and to make expert recommendations how to advance the field towards establishing clinical impact. \n\n\n\n\n\n\n\n\n\nRegister nowEnrol in the online course now for free! Register now\n\n\n\n\n\n\n\nFaculty\n\n\n\n\n\n\nCecilia BoccaliniSpeaker \n\n\n\n\n\nPaul BoonSpeaker \n\n\n\n\n\nAngelaBradshawSpeaker \n\n\n\n\n\nDiegoCecchinSpeaker \n\n\n\n\n\nJavierArbizuSpeaker \n\n\n\n\n\nFedericaAgostaSpeaker \n\n\n\n\n\n\n\n\n\nMatthiasBrendelSpeaker \n\n\n\n\n\nRikOssenkoppeleSpeaker \n\n\n\n\n\nSebastianEngelborghsSpeaker \n\n\n\n\n\nAlexanderDrzezgaSpeaker \n\n\n\n\n\nNicolaiFranzmeierSpeaker \n\n\n\n\n\nGiovanniFrisoniSpeaker \n\n\n\n\n\n\n\n\n\nValentina GaribottoSpeaker \n\n\n\n\n\nTakeshiIwatsuboSpeaker \n\n\n\n\n\nShorenaJanelidzeSpeaker \n\n\n\n\n\nFrankJessenSpeaker \n\n\n\n\n\nRenaudLa JoieSpeaker \n\n\n\n\n\nSilviaMorbelliSpeaker \n\n\n\n\n\n\n\n\n\nVincentPlance Speaker \n\n\n\n\n\nLucaRoccatagliataSpeaker \n\n\n\n\n\nPedroRosa-NetoSpeaker \n\n\n\n\n\nPhilipScheltensSpeaker \n\n\n\n\n\nJoySniderSpeaker \n\n\n\n\n\nCharlotteTeunissenSpeaker \n\n\n\n\n\n\n\n\n\nNellekeTolboom Speaker \n\n\n\n\n\nElsmariekevan de GiessenSpeaker \n\n\n\n\n\nKoen van LaereSpeaker \n\n\n\n\n\nAndrea VarroneSpeaker \n\n\n\n\n\nIgorYakushevSpeaker
URL:https://esmit.eanm.org/event/eanm-focus-meeting-7-molecular-imaging-for-a-personalised-treatment-in-alzheimers-disease/
CATEGORIES:Clinical Nuclear Medicine,Self-paced Online Course
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Vienna:20261231T000000
DTEND;TZID=Europe/Vienna:20261231T235900
DTSTAMP:20260525T223814
CREATED:20220901T101846Z
LAST-MODIFIED:20251016T123526Z
UID:1315-1798675200-1798761540@esmit.eanm.org
SUMMARY:Fundamentals of Research in Imaging and Theranostics – Part 1: Research Design
DESCRIPTION:UEMS EACCME has granted the accreditation of 4 CME credits for this event. \n\n\n\nThis online course is part of a long line of research methodology which is aimed at providing interested participants with information about the preclinical development and clinical translation\, as well as the design\, conductance and reporting of clinical research trials\, with a specific emphasis on radiopharmaceuticals for both diagnostic and therapeutic applications.  \n\n\n\nThese first two modules will represent part one of the course.  \n\n\n\nModule 1 will focus on the entire path from preclinical development to clinical translation of an imaging compound\, including the preclinical studies needed for the selection of a new candidate for clinical translation\, an overview of EU legislation on radiopharmaceuticals for diagnosis and therapy\, and the assessment of quality data and non-clinical data (pharmacology\, dosimetry and toxicology) for the IMP dossier.  \n\n\n\nModule 2 will be focused on the design of a proper trial. It will cover: the definition of objectives\, aims\, endpoints\, population\, statistical methods and examples of trial design schemes\, as well as dosimetry as far as healthy organs and in case of therapy tumour-absorbed dose. It will have a special focus on phase 0\, phase 1-2 trial\, early clinical phase 0-1-2 and investigator-driven clinical trial. \n\n\n\n \n\n\n\n\n\n\n\nSave yourself a seatEnter the eLearning store to register for the course. Having trouble? See the short tutorial here. Register now!\n\n\n\n\n\n\n\n\n\nLearning Objectives:\n\n\n\nLearn about: \n\n\n\n\nPreclinical development and clinical translation of radiopharmaceuticals \n\n\n\nThe legislation on radiopharmaceuticals with a specific focus on the European scenario \n\n\n\nRequirements of IMPD for radiopharmaceuticals for imaging agents and theranostic/therapeutic molecules Interpretation of preclinical data to properly design and plan the clinical trial \n\n\n\nPhase 0\, phase 1 and phase 2 clinical trials with radiopharmaceuticals design \n\n\n\nPhase 0\, phase 1 and phase 2 clinical trials with radiopharmaceuticals conductance \n\n\n\nGMP\, GLP and GCP principles \n\n\n\nImportance of radioprotection and dosimetric estimates in early phase clinical trials\n\n\n\n\n\n\n\n\n\n\n\n\nTarget Audience:\n\n\n\n\nResearchers\, scientists\, nurses\, pharmacologists\, radiopharmacists\, residents and specialists in Nuclear Medicine/Oncology/Radiology who want to understand how clinical trials with radiopharmaceuticals in the early phase are unique and how the corresponding documents and trial design should be appropriately planned.\n\n\n\n\n\n\n\n\n\n\nProgrammeClick to see the full event programme.  View the Programme\n\n\n\n\n\n\n\nFaculty\n\n\n\n\n\nPaola Anna ErbaUniversità degli Studi di Milano-Bicocca\, Italy \n\n\n\n\n\nSona BalogovaComenius University\, Bratislava\, Slovakia \n\n\n\n\n\nElisabeth von GuggenbergMedical University Innsbruck\, Austria \n\n\n\n\n\n\n\nMartina SolliniVita-Salute San Raffaele University\, Milan\, Italy \n\n\n\n\n\nLuigi AlojUniversity of Cambridge\, United Kingdom \n\n\n\n\n\nMeltem OcakIstanbul University\, Turkey \n\n\n\n\n\n\n\nPeter LavermanRadboud Universiteit Nijmegen\, The Netherlands \n\n\n\n\n\nJane SosabowskiQueen Mary\, University of London\, United Kingdom \n\n\n\n\n\nPetra KolencUniversity Medical Centre Ljubljana\, Slovenia \n\n\n\n\n\n\n\nClemens DecristoforoMedical University Innsbruck\, Austria \n\n\n\n\n\nPiotr GarnuszekPOLATOM\, Warsaw\, Poland \n\n\n\n\n\nRenata MikolajczakPOLATOM\, Warsaw\, Poland \n\n\n\n\n\n\n\nTheodosia MainaNCSR Demokritos\, Athens\, Greece \n\n\n\n\n\nMark KonijnenbergErasmus MC\, Rotterdam\, The Netherlands \n\n\n\n\n\n\n\n\n\nRegistration Details\n\n\n\nRegistration Fee\n\nCourse Fee              Free \n\n\n\n\n\n\n\n\n\nEvent Overview
URL:https://esmit.eanm.org/event/fundamentals-of-research-in-imaging-and-theranostics-part-1-research-design/
LOCATION:Online
CATEGORIES:Research Methods,Self-paced Online Course
END:VEVENT
END:VCALENDAR